Highlights:
-One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms
-New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months
-Michael Dake: Arch branded device
-Andrew Holden: Bioresorbable stents
-Profile: Janet Powell
